M. Romagnoli (Forli, Italy), P. Kirkham (Wolverhampton , United Kingdom), M. Rava (Villejuif, France), R. Dahl (Aarhus, Denmark)
Study design supporting the effectiveness of inhaled extra-fine beclomethasone/formoterol at the level of small airways of asthmatics
T. Popov, D. Petrova, T. Kralimarkova, Y. Ivanov, T. Popova, T. Odzhahova, Y. Ilieva, P. Yakovliev, T. Lazarova, O. Georgiev, M. Peneva, V. Hodzhev, E. Hodzheva, M. Staevska, V. Dimitrov (Sofia, Pleven, Varna, Stara Zagora, Plovdiv, Bulgaria)
|   |
The dynamics of oxidative stress markers in patients with bronchial asthma (BA) during the course of liposome nanoparticle admission (a randomized placebo-controlled study)
A. Lisitsa, I. Klimanov, S. Soodaeva, A. Averyanov (Moscow, Russian Federation)
| |
Study of antioxidant use in patients with asthma exacerbations
U. Farkhutdinov, S. Farkhutdinov (Ufa, Russian Federation)
| |
Formoterol-induced downregulation of the beta2-adrenoceptor in asthmatics with homozygous glycine-16 polymorphism
L. Fuso, A. Di Perna, A. Longobardi, A. Trovè, M. Bisceglia, B. Bibi, C. Angelozzi, F. D. Tiziano, R. Antonelli Incalzi (Rome, Italy)
| |
A double-blind, double-dummy, randomized study of beclomethasone/formoterol versus fluticasone/salmeterol in treatment of moderate to severe asthma in Taiwan
M. J. Hsieh, R. S. Lai, C. L. Wu, C. L. Lai, C. C. Wang, D. W. Peng, Y. H. Tsai (Linkou, Kaohsiung, Taipei, Dalin, Chiayi, Taiwan)
| |
One year following a real life experience of omalizumab for moderate to severe persistent allergic asthma in Malta
C. Gouder, L. West, S. Montefort (B'Kara, Malta)
| |
The impact of the addition of omalizumab on the utilization of healthcare resources by severe persistent asthma patients
S. Dyer, S. Packham, S. Davies (Swansea, United Kingdom)
| |
Improved effects of formoterol-budesonide combination on residual eosinophilic inflammation in asthmatic peripheral airway
H. Ohbayashi, M. Adachi (Mizunami, Tokyo, Japan)
| |
L-carnitine improves the asthma control in children with moderate persistent asthma
A. S. Bediwy, M. Al-Biltagi, M. Isa, N. Helaly, D. D. El Lebedy (Tanta, Cairo, Egypt)
| |
Efficacy of budesonide/formoterol maintenance and reliever therapy in mild asthma
C. Jenkins, G. Eriksson, E. D. Bateman, H. K. Reddel, M. R. Sears, M. Fagerås, M. B. Lindberg, P. M. O'Byrne (Sydney, Australia; Mölndal, Sweden; Cape Town, South Africa; Hamilton, Canada)
| |
Is sustained control of severe asthma possible? A composite score to assess 1-year of asthma control
A. Bourdin, N. Molinari, L. Halimi, G. Marin, M. Varin, A. S. Gamez, I. Vachier, P. Chanez (Montpellier, Marseille, France)
| |
The muscarinic M3 receptor regulates allergen-induced airway remodeling in mice
L. Kistemaker, S. Bos, M. Hylkema, P. Hiemstra, J. Wess, H. Meurs, H. Kerstjens, R. Gosens (Groningen, Leiden, Netherlands; Bethesda, United States Of America)
| |
Interim analysis of post-marketing surveillance of omalizumab in Japan
K. Ohta, H. Yoshisue, Y. Aoki, T. Irokawa, M. Ishigaki, M. Adachi, T. Miyamoto (Tokyo, Japan)
| |
Clinical and economic outcomes following 52-week add-on omalizumab
L. M. West, C. Gouder, S. Montefort (Msida, Malta)
| |
Tiotropium as add-on to inhaled corticosteroids significantly improves asthma control as reflected by the ACQ responder rate
H. A. M. Kerstjens, E. Bleecker, E. Meltzer, T. Casale, E. Pizzichini, O. Schmidt, M. Engel, L. J. Bour, C. B. Verkleij, P. M. Moroni-Zentgraf, E. D. Bateman (Groningen, Alkmaar, Netherlands; Winston-Salem, San Diego, Omaha, United States Of America; Santa Catarina, Brazil; Koblenz, Ingelheim am Rhein, Biberach an der Riss, Germany; Cape Town, South Africa)
| |
Validation of FEV1 spirometric endpoints as a measure of the anti-inflammatory and bronchodilatory effects of fluticasone/formoterol combination therapy
S. Dissanayake, B. Grothe, T. McIver, K. Kaiser (Cambridge, United Kingdom; Muttenz, Switzerland)
| |
Plume characteristics of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI
B. Johal, S. Murphy, J. Marshall (Cambridge, Oxfordshire, United Kingdom)
| |
Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses
P. Paggiaro, M. Engel, N. Tudoric, B. Forstner, E. Radeczky, V. Zubek, Z. Blahova, P. Moroni-Zentgraf (Pisa, Italy; Ingelheim am Rhein, Germany; Zagreb, Croatia; Wels, Vienna, Austria; Százhalombatta, Hungary; Ridgefield, United States Of America)
| |
Pharmacokinetic and pharmacodynamic evaluation after administration of beclomethasone dipropionate and formoterol fumarate as fixed or free metered-dose inhaler combination in adolescent asthma
P. Kuna, G. Lucci, M. Govoni, R. Baronio, E. Carzana, A. Elgalal, I. Stelmach (Lodz, Parma, Italy; Lodz, Poland)
| |
Effect of resolvin D1 on leukotriene D4-induced constriction of rat and human bronchioles
M. Jannaway, C. Torrens, J. Warner, A. Sampson (Southampton, United Kingdom)
| |